Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCC Cyclacel Pharmaceuticals, Inc. daily Stock Chart
CYCC [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.92 Insider Own17.53% Shs Outstand3.82M Perf Week-42.39%
Market Cap6.80M Forward P/E- EPS next Y-1.57 Insider Trans146.96% Shs Float3.67M Perf Month-58.12%
Income-10.50M PEG- EPS next Q- Inst Own21.10% Short Float9.84% Perf Quarter-66.03%
Sales0.70M P/S9.71 EPS this Y34.70% Inst Trans110.61% Short Ratio1.46 Perf Half Y-64.61%
Book/sh3.00 P/B0.59 EPS next Y30.20% ROA-53.70% Target Price7.00 Perf Year-62.92%
Cash/sh3.32 P/C0.54 EPS next 5Y- ROE-73.50% 52W Range1.71 - 10.90 Perf YTD-66.35%
Dividend- P/FCF- EPS past 5Y-10.40% ROI-85.10% 52W High-83.67% Beta3.38
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin- 52W Low4.09% ATR0.32
Employees13 Current Ratio4.10 Sales Q/Q-25.00% Oper. Margin- RSI (14)18.01 Volatility8.46% 7.52%
OptionableNo Debt/Eq0.00 EPS Q/Q64.00% Profit Margin- Rel Volume7.56 Prev Close1.91
ShortableYes LT Debt/Eq0.00 EarningsAug 09 AMC Payout- Avg Volume248.33K Price1.78
Recom2.00 SMA20-47.43% SMA50-56.65% SMA200-60.81% Volume1,877,421 Change-6.81%
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Nov-27-07Reiterated Cantor Fitzgerald Buy $14 → $10.50
Aug-10-07Reiterated Cantor Fitzgerald Buy $12 → $14
Jun-04-07Reiterated Needham & Co Buy $9 → $12
Apr-23-07Initiated Lazard Capital Buy $11
Apr-10-07Initiated Cantor Fitzgerald Buy $12
Jul-21-17 02:00PM  Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option GlobeNewswire +11.70%
Jul-20-17 08:10AM  Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc. Accesswire
May-19-17 11:05AM  Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:16PM  Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire
12:00PM  Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-05-17 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results GlobeNewswire
Apr-11-17 09:59AM  Company News for April 11, 2017 Zacks
Apr-07-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals Accesswire
Apr-05-17 04:37PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : April 5, 2017 Capital Cube -18.24%
Apr-04-17 04:40PM  Rising Biotechs: Paratek Among Stocks Surging On Trial Results Investor's Business Daily +27.26%
01:00PM  Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 GlobeNewswire
12:24PM  Adam Feuerstein Unloads On Cyclacel Pharmaceuticals, Will Break Down Its Manipulation On PreMarket Prep Benzinga
09:15AM  Novocure and Cyclacel Pharmaceuticals Surge on Positive FDA Trial News Accesswire
09:01AM  Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017 Capital Cube
Apr-03-17 11:32AM  Cyclacel's CYC065 Succeeds in Lung Cancer Study Investopedia +74.46%
Apr-02-17 01:00PM  Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways GlobeNewswire
Mar-28-17 07:36PM  Edited Transcript of CYCC earnings conference call or presentation 28-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
04:16PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
Mar-21-17 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-13-17 04:31PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events +7.09%
Mar-07-17 07:00AM  Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI GlobeNewswire +9.07%
Feb-24-17 01:35PM  Heres What Happened With Cyclacel Pharmaceuticals Inc (CYCC) And Nivalis Therapeutics Inc (NVLS) at Insider Monkey
09:23AM  Cyclacel Tanks on Leukemia Drug Failure at Investopedia
Feb-23-17 09:20AM  Biotech Movers: Shire Rises on Encouraging Angioedema Results -25.14%
08:17AM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:50AM  Cyclacel's stock plunges after disappointing trial results of its cancer treatment at MarketWatch
07:19AM  Cyclacel's leukemia drug for elderly patients fails in key study
06:57AM  Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia GlobeNewswire
Feb-06-17 07:00AM  Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-19-17 12:47PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : January 19, 2017
Dec-29-16 01:43PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 29, 2016
Dec-22-16 04:32PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-13-16 12:43PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2016
Dec-09-16 04:32PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Dec-06-16 04:10PM  Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy GlobeNewswire
Dec-01-16 07:00AM  Cyclacels Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia GlobeNewswire +5.84%
Nov-23-16 01:04PM  CYCLACEL PHARMACEUTICALS, INC. Financials
12:51PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 23, 2016
Nov-21-16 11:53AM  Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-18-16 04:31PM  Moleculin Biotech gets good verbal Ok from FDA which should cut time to Phase 1/2 trial down -14.87%
12:22PM  Heres Why Cyclacel Pharmaceuticals Inc (CYCC) Could Have A Rough December at Insider Monkey
Nov-14-16 05:04PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement +8.91%
04:05PM  Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
Nov-07-16 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results GlobeNewswire
Sep-12-16 04:16PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Sep-06-16 07:00AM  Cyclacels CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016 GlobeNewswire -7.71%
Aug-30-16 05:05PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Aug-23-16 09:00AM  Movers and Shakers In Biotech: Cyclacel Pharmaceuticals Inc (CYCC) and Corium International Inc (CORI) at Insider Monkey -10.39%
Aug-22-16 12:36PM  Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism +19.48%
12:18PM  Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today
Aug-19-16 12:49PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : August 19, 2016 -7.72%
Aug-18-16 11:12AM  Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 -6.12%
Aug-11-16 05:04PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -6.47%
Aug-10-16 04:17PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results GlobeNewswire
Aug-03-16 07:00AM  Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results GlobeNewswire
Aug-02-16 07:00AM  Cyclacels CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers GlobeNewswire
Jul-06-16 05:02PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jun-23-16 04:39PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Mater
Jun-16-16 07:00AM  Cyclacel Regains Compliance With Nasdaq Continued Listing Requirements GlobeNewswire -7.47%
Jun-06-16 04:13PM  Cyclacel Pharma (CYCC) Stock Skyrockets 50% on Positive Phase 1 Data +46.07%
12:07PM  Why Are Traders Piling Into These Stocks? at Insider Monkey
10:00AM  Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO GlobeNewswire
Jun-01-16 01:32PM  Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016
May-31-16 07:03AM  Splits Calendar: Cyclacel Pharma splits before market open today (1:12 ratio) -9.37%
May-27-16 05:06PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to -6.69%
05:00PM  Cyclacel Announces Reverse Stock Split GlobeNewswire
May-19-16 07:00AM  Cyclacels Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-13-16 04:15PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report +5.69%
May-11-16 04:18PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement +6.64%
04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q1 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
May-04-16 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results GlobeNewswire
Apr-18-16 09:00AM  Cyclacels Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors GlobeNewswire
Apr-11-16 09:05AM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Cyclacel Announces Receipt of Nasdaq Extension GlobeNewswire
Apr-08-16 01:43PM  Edited Transcript of CYCC earnings conference call or presentation 24-Mar-16 8:30pm GMT
Mar-24-16 04:21PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:16PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results at noodls
04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
07:07AM  Q4 2015 Cyclacel Pharmaceuticals Inc Earnings Release - Time Not Supplied
Mar-17-16 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
Mar-01-16 03:58PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Cyclacel Pharmaceuticals, Inc. Business Wire
Feb-05-16 04:32PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule
04:20PM  Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing GlobeNewswire
Feb-02-16 07:00AM  Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-11-16 07:00AM  Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 GlobeNewswire -10.50%
Jan-06-16 10:44AM  Value Strategies in 2015: NCAV up 30%, Destruction for the others
Dec-31-15 05:21PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events
Dec-14-15 07:00AM  Molecular Basis for Development of Cyclacels CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium GlobeNewswire
Dec-07-15 11:16AM  Cyclacel Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Nov-23-15 07:00AM  CYC065, Cyclacels Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models GlobeNewswire +8.77%
Nov-12-15 04:12PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement -6.07%
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; in Phase II clinical trial for myelodysplastic syndromes; and in Phase I/II clinical trial in combination with seliciclib, a drug candidate to treat solid tumors. Its oncology development programs also comprise Seliciclib, an oral inhibitor of cyclin dependent kinase (CDK) 2/9 enzymes, which are central to the process of cell division and cell cycle control that has completed a Phase IIb clinical trial; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial targeting CDK2/9 enzymes with potential utility in hematological malignancies and solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage; and Aurora Kinase inhibitors, a serine/threonine protein kinases that focuses on cell division or mitosis for the treatment of cancer. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Eastern Capital LTD10% OwnerJul 19Buy2.00850,0001,700,0002,167,261Jul 21 05:37 PM
TANG KEVIN C10% OwnerFeb 23Buy4.34134,200582,079559,900Feb 27 05:10 PM